Hologic, Inc. Stock

Equities

HOLX

US4364401012

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 11:39:24 2024-04-18 am EDT 5-day change 1st Jan Change
74.91 USD -0.01% Intraday chart for Hologic, Inc. -3.51% +5.04%
Sales 2024 * 4.03B Sales 2025 * 4.25B Capitalization 17.59B
Net income 2024 * 798M Net income 2025 * 845M EV / Sales 2024 * 4.23 x
Net cash position 2024 * 553M Net cash position 2025 * 1.37B EV / Sales 2025 * 3.82 x
P/E ratio 2024 *
22.4 x
P/E ratio 2025 *
20.9 x
Employees 6,990
Yield 2024 *
-
Yield 2025 *
-
Free-Float 77.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.25%
1 week-3.47%
Current month-3.90%
1 month-1.30%
3 months+2.56%
6 months+8.58%
Current year+4.86%
More quotes
1 week
74.70
Extreme 74.7
78.35
1 month
74.70
Extreme 74.7
79.22
Current year
70.53
Extreme 70.53
79.22
1 year
64.02
Extreme 64.02
87.88
3 years
59.78
Extreme 59.78
87.88
5 years
26.49
Extreme 26.49
87.88
10 years
20.24
Extreme 20.24
87.88
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 13-12-06
Director of Finance/CFO 54 05-12-31
Chief Operating Officer 44 17-08-31
Members of the board TitleAgeSince
Chief Executive Officer 60 13-12-06
Director/Board Member 69 17-05-14
Director/Board Member 63 16-11-30
More insiders
Date Price Change Volume
24-04-18 75.05 +0.17% 336 841
24-04-17 74.92 -0.25% 1,697,868
24-04-16 75.11 -3.13% 1,764,609
24-04-15 77.54 +0.27% 1,605,404
24-04-12 77.33 -0.58% 1,573,811

Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT

More quotes
Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows: - molecular diagnostics (46.7%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin; - breast health (35.5%): digital mammography and breast biopsy solutions and systems; - gynecological surgery (15%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures; - bone health (2.8%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment. Net sales break down by source of revenue between sales of products (81.4%) and services (18.6%). Net sales are distributed geographically as follows: the United States (75.9%), Europe (12.9%), Asia/Pacific (6.3%) and other (4.9%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
74.92 USD
Average target price
84.27 USD
Spread / Average Target
+12.48%
Consensus